Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 3
Therapeutics and Clinical Risk Management
ISSN: 1178-203X
- View all (2328)
- Volume 20, 2024 (20)
- Volume 19, 2023 (91)
- Volume 18, 2022 (104)
- Volume 17, 2021 (134)
- Volume 16, 2020 (134)
- Volume 15, 2019 (154)
- Volume 14, 2018 (271)
- Volume 13, 2017 (188)
- Volume 12, 2016 (217)
- Volume 11, 2015 (210)
- Volume 10, 2014 (113)
- Volume 9, 2013 (57)
- Volume 8, 2012 (47)
- Volume 7, 2011 (59)
- Volume 6, 2010 (66)
- Volume 5, 2009 (102)
- Volume 4, 2008 (148)
- Volume 3, 2007 (126)
- Volume 2, 2006 (47)
- Volume 1, 2005 (40)
Archive: Volume 2, 2006
Effectiveness of lifestyle measures in the treatment of gastroesophageal reflux disease – a case series
Madeleine Nowak, Petra Büttner, Simone Harrison, Kym Daniell, Beverly Raasch, Rick Speare
Therapeutics and Clinical Risk Management 2006, 2:329-334
Published Date: 15 September 2006
An assessment of the cost-utility of therapy for psoriasis
Stefan C Weiss, Wingfield Rehmus, Alexa B Kimball
Therapeutics and Clinical Risk Management 2006, 2:325-328
Published Date: 15 September 2006
Cost-effectiveness of hypothetical new cancer drugs in patients with advanced small-cell lung cancer: results of a markov chain model
Carin A Uyl-de Groot, Joseph McDonnell, Guul ten Velde, David Radice, Harry J M Groen
Therapeutics and Clinical Risk Management 2006, 2:317-323
Published Date: 15 September 2006
Impact of introducing anticoagulation-related prescribing guidelines in a hospital setting using academic detailing
Gregory William Roberts, Robert Adams
Therapeutics and Clinical Risk Management 2006, 2:309-316
Published Date: 15 September 2006
Frovatriptan: a review of pharmacology, pharmacokinetics and clinical potential in the treatment of menstrual migraine
Ebrahim A Balbisi
Therapeutics and Clinical Risk Management 2006, 2:303-308
Published Date: 15 September 2006
Oral paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease
Steven Cheng, Daniel Coyne
Therapeutics and Clinical Risk Management 2006, 2:297-301
Published Date: 15 September 2006
Management of age-related osteoporosis and prevention of associated fractures
Eric J MacLaughlin, Rebecca B Sleeper, Danny McNatty, Cynthia L Raehl
Therapeutics and Clinical Risk Management 2006, 2:281-295
Published Date: 15 September 2006
Bortezomib (Velcade™) in the treatment of multiple myeloma
Antonia Field-Smith, Gareth J Morgan, Faith E Davies
Therapeutics and Clinical Risk Management 2006, 2:271-279
Published Date: 15 September 2006
Progress in the development of a cervical cancer vaccine
Ursula Winters, Richard Roden, Henry Kitchener, Peter Stern
Therapeutics and Clinical Risk Management 2006, 2:259-269
Published Date: 15 September 2006
Cancer treatment-induced mucositis pain: strategies for assessment and management
Debra J Harris
Therapeutics and Clinical Risk Management 2006, 2:251-258
Published Date: 15 September 2006
Alendronate sodium in the management of osteoporosis
P J J Prinsloo, DJ Hosking
Therapeutics and Clinical Risk Management 2006, 2:235-249
Published Date: 15 September 2006
Oxycodone controlled release in cancer pain management
Giuseppe Biancofiore
Therapeutics and Clinical Risk Management 2006, 2:229-234
Published Date: 15 September 2006
Editorial ||FREE PAPER||
Garry Walsh
Therapeutics and Clinical Risk Management 2006, 2:227-228
Published Date: 15 September 2006